IPOs/Recent Issues: SEQUENOM –

San Diego, CA

Went public 2/1/2000 at $26 apiece

Filing Range: 5 mil. shares @ $23 to $25

Shares Outstanding: 22.84 mil. shares

Underwriters: Warburg Dillon Read

Robertson Stephens/SG Cowen


(Data except per-share in $ thousands)


12/97 12/98 9/98 9/99

Total Revenue $527 $351 $126 $81

Net Loss -5,117 -10,271 -6,003 -15,386

Net Loss Per Share -22.62 -33.33 -20.12 -39.41

The Company:

Sequenom is an industrial genomics company that focuses on the large scale commercial use of the knowledge of DNA variations for improving health, agriculture and livestock. These variations are the origin of most differences between individuals, including disease predispositions and variations in drug responses. The most common varations are called single nucleotide polymorphisms, of SNPs. SNPs represent the smallest possible genetic change, and occur where the DNA molecules of different persons vary at a single location. The company’s MassArray system, which compares and reports genotypes at a rate of three seconds per sample, provides a high throughput SNP analysis at high speeds. Sequenom’s strategy is to capitalize on the quickly emerging demand for SNP analysis in the areas of drug discovery and development, DNA diagnostics, patient stratification by genetic traits, clinical trials, seed development and livestock breeding. In October 1999, Sequenom contracted for the first sale of a MassArray system and commercial sales were launched during the fourth quarter of 1999.


Estimated net proceeds of $77.8 million will be used for general corporate purposes, including hiring additional sales and customer support personnel, facilities expansion, product development, research and development of additional products, patent prosecution expenses and working capital.

Venture Backers:

TVM Techno Venture Management, Alpinvest Holding N.V., Lombard Odier & Cie Global Life Sciences LP

Board Members:

Helmut Schuhsler, TVM Techno Venture Management 1996

Ernst-Gunter, Afting Global Life Sciences LP 1998